



Prof. Abha Majumdar
**Director, Center of IVF and Human Reproduction
Sir Ganga Ram Hospital, New Delhi, INDIA**

President's Medal for best medical graduate of year 1970-75

Award from DMA on Dr. B.C Roy's birthday: outstanding contribution to medicine, 1999

Vikas Ratan Award by Nations economic development & growth society 2002

Chitsa Ratan Award by International Study Circle in 2007

Life time Medical excellence award Obs & Gyne by Hippocrates foundation 2014

Abdul Kalam gold medal by Global Economic Progress & Research Association 2015

Rashtriya Gaurav Gold Medal award October 2017 by GEPR

Distinguished teacher of excellence award for PG medical education by ANBAI & NBE
doctors day on 5th Sept 2017 and **Inspiring Gynecologist of India** by the Economic Times
on the same date in 2018

Course director for post doctoral **Fellowship in Reproductive Medicine** by NBE, since 2007, IFS since 2014, ISAR 2014 and by FOGSI for basic & advanced infertility training since 2008.

Member of Editorial board of '**IVF Worldwide**', peer reviewer for '**Journal of Human Reproductive Sciences**', Member of advisory board for '**Journal of Fertility Science & Research**' and consultant advisor for queries to NDTV.com

Field of interest: Infertility, ART, Reproductive endocrinology, Endoscopic surgery for pelvic resurrexion and ART.

Super Speciality & Research Block

SIR GANGA RAM
HOSPITAL

DR. ABHA MAJUMDAR

MBBS, MS, FICS

Director & Head of IVF Department
IVF Sir Ganga Ram Hospital

Expertise

Infertility, assisted reproductive techniques,
reproductive endocrinology, endoscopic surgery
for pelvic resurrexion.



Director Centre of IVF and Human Reproduction

Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, 110060

Ph: 011 4225 4000/ 011 4225 1800/ 011 4225 1777/ 8375990881

Website: www.ivfgangaram.com



IVF SIR GANGARAM HOSPITAL

Smart stimulation of ovary to fit the budget

Prof Abha Majumdar

Director and Head

Centre of IVF and Human Reproduction



Sir Ganga Ram Hospital

New Delhi



Nobel Prize winner: The work of British physiologist [Robert G. Edwards](#) waited longest to be recognized. His award for medicine comes 32 years after he figured out how to create the beginnings of human life outside the uterus through in vitro fertilization.

Single oocyte Single embryo
Single baby



IVF started to develop fast with the aim of maximizing pregnancy rates per cycle

COH for **higher number of oocytes, thus more embryos**

- Use of un-physiological high doses of gonadotropins with time consuming protocols
- Higher costs, more office visit's,
- More tests and patient discomfort
- Higher risk of OHSS
- Very high risk of multiple gestation

Rapid progression of protocols and technology



This magic wheel had to slow down



Definition of success in IVF started shifting from pregnancy rate per cycle towards achieving healthy singleton child without complications per started cycle

For achieving this aim the first change had to be in stimulation protocols with the aim of:

- Less oocytes
- less cost
- less pain /stress
- Less complications
- Obtaining a good oocyte / embryo/ implantation rate
- Good pregnancy rates

Further progression of technology aimed at minimizing complication rate and maintaining pregnancy

*Careful
individualized
COH*

IMAGE
envision
.com

Progression of technology

Conventional stimulation protocols

Conventional regimes

Aims at >8 oocytes but high complication OHSS



Milder stimulation protocols

Mild stimulation regimes

Aims at < 8 oocytes but needs very good lab conditions




Individualized stimulation protocols

Individualized COS (iCOS)

Best live birth rate with low complication rate; OHSS

Louise Brown,
was born in
1978 without
any fertility
drugs



Individualized ovarian stimulation will depend upon:

Type of response expected

Age

Weight

Ovarian reserve test

Underlying pathology for IVF

Severe endometriosis

Male factor

Oocyte donor

Hormonal imbalance

Hypo-gonadotropic
hypo-gonadism)

Low cost IVF to fit all
pockets

Time constraints of patient

Oncologic/thrombotic
needs

Fertility preservation

Identifying response

Hyper responder

Underlying PCOS
Thin built
Age < 30
FSH < 8miu/ml
AMH > 25pmol/l
AFC > 12
Previous hyper response

Poor responder

Regular or shortening cycles
Obese
Age > 37
FSH > 12miu/ml
AMH < 5pmol/l
AFC < 6
Previous poor response

Individualized ovarian stimulation will depend upon:

Type of response expected

Age

Weight

Ovarian reserve test

Previous response to

Hormonal imbalance

PCOS/LH hypersecretion

Hypo-gonadotropic hypo-gonadism)

Underlying pathology for IVF

Severe endometriosis

Male factor

Oocyte donor
Low cost IVF to fit all pockets

Time constraints of patient

Oncologic/thrombotic needs

Fertility preservation

Monitoring

Injectable
gonadotropins and
analogues

C

O


S

T


Embryology:
handling too many
oocytes, increase
media, increase
freezing of embryos

Complications of
hyperstimulation


Infertility is an epidemic in India



≈ 4.2%
Indian
population
suffer from
infertility



≈ 1% of
infertile
couples
seek IVF



≈ 0.05%
india's
total
populatio
n seeks
IVF

We are doing **1 lac** cycles a year
But we need **93.3 lac** cycles a
year

Source: EY 2015 report, ETPrime
analysis

Low cost IVF to fit all pockets

In order to give some chance of pregnancy to infertile couples who simply cannot afford conventional IVF-ET with injectable drugs and the consequent cost of complications, we will have to bring in IVF-ET with low cost drugs and minimal injections.

This will not only decrease the total cost of the procedure, but will be taken up by more needy couples even though the success rates may appear compromised.

Natural cycle IVF (spontaneous ovulation)

1. No stimulation (oral medications or gonadotropins)
2. hCG trigger pre oocyte retrieval
3. No anaesthesia nor anaesthetist (I/V medicine for pain relief -1 or 2 follicles)
4. No luteal support

The basic techniques of oocyte retrieval, insemination, embryo culture, embryo transfer, and pregnancy testing after embryo transfer are very similar to those used in conventional IVF-ET.

**Very good lab performance to enable 10 to 15% pregnancy rates.
Cost of IVF lab charges 50 to 66% lower (consumables & procedural)
Clinicians charges lower by 50 to 66% to sustain such programs**

Low Success Rate of ART, an Illusion, a Reality or Simply a Too High Expectation?

Mohammad Reza Sadeghi, Editor-in-chief

Copyright and License information ►

Assisted reproductive technologies have spread worldwide to help infertile couples but access to these advanced treatments is of varying degrees in different countries. Access to infertility treatment is very limited and insurance coverage of these treatments is insufficient in developing, underdeveloped and low-income countries.

Why do we need ovarian stimulation?

Human Reproduction, Vol.31, No.10 pp. 2261–2267, 2016

Advanced Access publication on September 2, 2016 doi:10.1093/humrep/dew184

human
reproduction

ORIGINAL ARTICLE *Infertility*

Live birth and perinatal outcomes following stimulated and unstimulated IVF: analysis of over two decades of a nationwide data

Sesh Kamal Sunkara^{1,*}, Antonio LaMarca², Nikolaos P. Polyzos³, Paul T. Seed⁴, and Yakoub Khalaf⁵

Data from Human Fertilisation and Embryology Authority (HFEA) 1991 to 2011


5,91,003 fresh IVF ± ICSI cycles

- ▶ 5,84,835 stimulated IVF cycles
- ▶ 6,168 unstimulated IVF cycles

Chances of no oocytes retrieved

- 44.2% - unstimulated cycles
- 7.1% - stimulated cycles

- To achieve live birth
 - 3.5 times more unstimulated IVF cycles required compared to stimulated IVF
- To achieve one singleton live birth
 - 2.9 times more unstimulated IVF cycles required compared to stimulated IVF.
- TTP shorter with stimulated IVF cycle



There are several slightly different ways in which IVF-ET can be performed with limited use of injectable gonadotropins in combination to oral drugs for enhancing ovulation as well as controlling spontaneous LH surge.

There are no universally agreed upon definitions to describe minimal stimulation protocols for IVF.

Minimal stimulation low cost protocols

Advantages

Inexpensive oral clomiphene followed by low dose gonadotropin and hCG trigger or just the hCG trigger shot alone.

- fewer injections,
- fewer days of monitoring,
- Less exposure to medications to developing eggs and the developing endometrium.

Who benefits

- Low responders who do not recruit many follicles even with full stimulation,
- High responders who are at a markedly increased risk of ovarian hyperstimulation syndrome,
- Patients who are not interested in embryo cryopreservation
- Women who want to limit the number of eggs to be fertilized, for ethical or religious reasons

Minimal stimulation IVF-
ET SART

Oral low cost drugs to **replace use of analogues** to prevent LH surge:

1. CC: day 3 to trigger
2. Progestogen: day 3 to trigger

Use of oral low cost drugs to **potentiate stimulation** of gonadotropins:

1. CC for first 5 days
2. Letrozole for first 5 days

Lower gonadotropin

Less monitoring

Lower lab. consumption

Lower complications

Counter balanced by


Need to vitrify all embryos and transfer them in subsequent natural cycles if analogues not used

ALTERNATIVE PROTOCOLS ESPECIALLY LOW COST FOR POOR OR NORMAL RESPONDERS




**Kato O
protocol**

DYG as a part
of a progestin-
primed
ovarian
stimulation
protocol for
IVF



PPOS




**Clomiph
ene**


Obtain a few high quality eggs, avoid risks of OHSS, reduce cost of drugs & number of injections.



CC 50 mgs from day3, till hCG trigger + FSH 150 iu on day 8 every alternate day.



approach to circumvent cost but maintain



stimulate good number of follicles and block LH


Japanese Minimal Stimulation Protocol
Teramato S, Kato O
43,433 cycles
OR=83%, CR=64%,
mean no of oocyte=2.2 and
LBR=11.1%

Shanghai protocol

Dual stimulation

Follicular & luteal stimulation with GnRHa trigger in first stimulation

Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation



Clomiphene citrate

[PDF] Use of clomiphene to prevent premature luteinizing hormone surge ...

www.ejmanager.com/mnstemps/89/89-1460112205.pdf?ft=1464877999 ▼

by S Bhandari - 2017 - Cited by 2 - Related articles

Jun 1, 2016 - considerably, the ideal method to prevent premature luteinizing hormone ... use of antagonist. Keywords: Clomiphene citrate, LH surge, In vitro fertilization, Ovarian stimulation ... the cost was bore by the institute. The oocyte ...

Use of clomiphene to prevent premature luteinizing hormone surge ...

www.ijrcog.org/index.php/ijrcog/article/view/1255 ▼

by S Bhandari - 2017 - Cited by 2 - Related articles

Use of clomiphene to prevent premature luteinizing hormone surge during controlled ... Clomiphene citrate, LH surge, In vitro fertilization, Ovarian stimulation ... to the Standard Long Stimulation Protocol with a Significant Reduction in Cost.

Use of clomiphene-based stimulation protocol in oocyte donors: A ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070397/> ▼

by A Singh - 2016 - Cited by 2 - Related articles

Clomiphene by its antiestrogen effect on the pituitary helps ovarian stimulation by releasing FSH; at the same time, it prevents the release of LH and thus prevents premature LH surge which can cause premature ovulation. This property of clomiphene can be used in IVF stimulation protocol.

Abstract · INTRODUCTION · MATERIALS AND METHODS · RESULTS

Clomiphene citrate in LH surge suppression for women undergoing ...

<https://www.sciencedirect.com/science/article/pii/S1110569017303060>

by NM Shams-Eldeen - 2018 - Related articles

Feb 1, 2018 - Keywords. Clomiphene. COS. LH surge. Premature luteinization in order to prevent LH surge without affecting the IVF/CSI cycle outcomes.

Journal List › J Hum Reprod Sci › v.8(3); Jul-Sep 2015 › PMC4601172



J Hum Reprod Sci. 2015 Jul-Sep; 8(3): 142–145.

doi: [[10.4103/0974-1208.165151](https://doi.org/10.4103/0974-1208.165151)]

PMCID: PMC4601172

PMID: [26538856](https://pubmed.ncbi.nlm.nih.gov/26538856/)

Clomiphene based ovarian stimulation in a commercial donor program

[Shruti Gupta](#), [Ruma Satwik](#), [Abha Majumdar](#), [Shweta Mittal](#), and [Neeti Tiwari](#)

PPOS

Stimulation with gonadotropin with didrogestrone 10mg/d to stop LH surge from day 2 daily till trigger


[Hum Reprod.](#) 2018 Feb 1;33(2):229-237. doi: 10.1093/humrep/dex367.

New application of dydrogestrone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.

[Yu S](#), [Long H](#), [Chang HY](#), [Liu Y](#), [Gao H](#), [Zhu J](#), [Quan X](#), [Lyu Q](#), [Kuang Y](#), [Ai A](#)

To make IVF affordable to all

Compromised results
even with
good labs



Mild stimulation
protocols

Good results
less cost
least
complications



Development of
newer COS
protocols

Good results
but increase
cost and
complications



Conventional iCOS

Thank you

Amazinda